• Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Cellular Components of the Anti-Tumor Immune Response Oct 30, 2003 Julie R. Ostberg, Ph.D. Dept of Immunology Roswell Park Cancer Institute
  • 2. Leukocytes- white blood cells Granulocytes 1. neutrophils 2. eosinophils Plasma 3. basophils Non-granulocytes After centrifugation, leukocytes are found in 4. monocytes the “buffy coat” 5. lymphocytes RBCs
  • 3. Granulocytes (Polymorphonuclear Leukocytes) • Neutrophils (PMNs) – Phagocytic and bactericidal – Most numerous leukocytes in blood • Eosinophils/Basophils – Activated by IL-5 and Ag crosslinking of Fc ε R bound IgE
  • 4. Neutrophils in Tumor Immunology • IL-2 secreting tumors are massively infiltrated with PMNs • Exocytosed granules of PMNs in contact with dying tumor cells E. Di Carlo et al Blood 97:339 (2001)
  • 5. Eosinophils in Tumor Immunology Efficacy of Local Cisplatin/IL-2 administration for treatment of equine sarcoids correlates with eosinophilic infiltrate TJP Spoormakers et al Cancer Immunol Immunother 52:179 (2003)
  • 6. Mast Cells in Tumor Immunology • Reside in connective tissue • Activated by Ag crosslinking of Fc ε R bound IgE • Degranulation releases vasoactive and inflammatory mediators • Accumulation at tumor periphery associated with enhanced tumor growth/ invasion and angiogenesis Reviewed by D. Ribatti et al Br J Hematol 115:514 (2003)
  • 7. Monocytes/Macrophages in Tumor Immunology • Phagocytose opsonized cells/particles • Presents Ags to T cells • Tumor cytotoxic function stimulated with LPS, IFNγ , GM-CSF – Via NO, TNF • Capacity to stimulate angiogenesis may support growth of larger tumors • NO and ROS production suggested to suppress anti-tumor immunity Reviewed by AH Klimp et al Crit Rev Oncol Hematol 44:141 (2002), R Kiessling et al Cancer Immunol Immunother 48:353 (1999)
  • 8. Agents Produced by Innate Immune Cells that are ‘Toxic’ to Tumor Cells • ROIs • NO • Antimicrobial peptides • Acidic agents • Proteolytic enzymes • Pro-inflammatory cytokines/chemokines Note Paradox: Chronic release of these effector molecules may also result in immune cell dysfunction!
  • 9. Lymphocytes •Recognize specific • T-cells Ag determinants •Responsible for – helper CD4+ specificity and – cytotoxic CD8+ memory of the • B-cells adaptive immune – become antibody producing response plasma cells • NK cells – part of the innate immune response
  • 10. B Cell Activation • First signal for activation delivered through Ag receptor (membrane Ig) • Ag gets taken up and processed for presentation to T cells • Activated T cell then provides second signal for B cell activation • Note: some Ags provide two signals (e.g. LPS) without T cell help
  • 11. B-1 cells • Use a distinctive/limited set of gene rearrangements to make Ig receptors • Self-renewing in the periphery • Predominant lymphocyte in the peritoneal cavity (CD5+) • Make Ig responses mainly to polysaccharide antigens • Produce IgM without T cell help
  • 12. ADCC CMC Apoptosis
  • 13. Importance of Fcγ R in Tumor Immunity RA Clynes et al Nature Med 6:443 (2000) • Fc γ RIII = stimulatory – Fc γ R -/- mice lose Ab mediated tumor growth control • Fc γ RIIb = inhibitory – Fc γ R IIb -/- mice have enhanced Ab mediated tumor growth control
  • 14. T cell Activation • First signal for activation delivered through Ag receptor (TCR) • Second signal delivered through CD28 (co- stimulation)
  • 15. Helper T cells (TH) • CD4+ (bind MHC class II) • Influence/direct function of other cells • TH1 – Facilitate “cellular immunity” • Activate Mφ , induce B cells to produce opsonizing IgG2a – Secretion of IL-2, IFN- γ … • TH2 – Facilitates “humoral immunity” • Activate B cells to produce neutralizing IgG1 – Secretion of IL-4, IL-5, IL-10….
  • 16. Cytotoxic T Lymphocytes (CTL) • CD8+ (bind MHC class I) • Naïve cells activated by – Potent APCs (DCs) with high levels of costimulatory molecules – Weaker APCs in the presence of CD4+T cells which provide the costimulatory signals • Activated cell makes IL-2, driving its own proliferation/differentiation • Binding of TCR on activated/effector CTL to target cell MHC:peptide directs the focused release of effector molecules to the target cell
  • 17. T cells in Tumor Immunology CTL Th1 Th2 FasL CD40L Perforin CD40 Granzymes Fas cytokines cytokines Tumor Mφ B cell Direct Killing Ab Production ROI/NO Generation of TAA Production (survivin) specific Autologous CTL [SM Schmidt et al Blood 102:571 (2003)]
  • 18. γ / δ T cells • Most = CD4- CD8 – • Use a distinctive/limited set of gene rearrangements to make γ / δ T CR • TCR binds proteins directly (without MHC class I/II) • Reside in epithelia – Do NOT generally recirculate between blood and Lymph nodes • Knockout mice are more susceptible to skin cancer, suggesting role in immunosurveillance
  • 19. γ / δ T cells in Tumor Immunology Endogenous non-peptidic phosphorylated mevalonate metabolites in tumor cells activate γ / δ T cells – Blocking the activity of crucial enzyme in mevalonate pathway inhibits γ / δ T cell activation – Overproduction of these metabolites suggested to target cells with abnormal metabolisms for immune recognition H-J Gober et al J Exp Med 197:163 (2003)
  • 20. Regulatory T cells (Treg) • Revival of “suppressor T cells” • CD4+ CD25+ • Involved in maintanence of self-tolerance – Suppress proliferation of anti-CD3 stimulated T cells in vitro Reviewed by J-F Bach Nature Rev Immunol 3:189 (2003)
  • 21. Treg cells in Tumor Immunology • Removal of Treg cells evokes effective anti- tumor immunity in mouse models S Sakaguchi et al J Immunol 155:1151 (1995) • Cancer patients display increased CD4+ CD25+ T cell pool in peripheral blood – Patients had received neither immunosuppressive therapy or chemotherapy for 3 mo. AM Wolf Clin Cancer Res 9:606 (2003)
  • 22. Diversity of T cells with Regulatory Functions J-F Bach Nature Rev Immunol 3:189 (2003)
  • 23. NK cells • A.k.a. large granular lymphocytes • Mediate tumor cell cytotoxicity via perforin, TNF- α ( F asL and TRAIL?) • Early producers of IFN- γ (Th1 skewing) • Possess receptors for self molecules that inhibit their activation against “normal” cells – e.g., MHC class I • Activation depends on balance of signals from activating vs. inhibitory receptors – NKG2D, NKp44 = activating (human) – KIR, NKG2A = inhibitory (human)
  • 24. NK cells in Tumor Immunology B16 mouse tumor model reveals IL-12 mediated control of tumor metastasis to be dependent on NK cells – Used anti-NK1.1 Ab to deplete NK cells – Primary s.c. tumor growth not dependent on NK cells S-H Park et al J Immunol 170:1197 (2003)
  • 25. NK/T cells • Express both NK cell markers (NK1.1, CD56) as well as an invariant V α TCR (Vα 1 4 mouse, V α 24 human) • V α TCR recognizes the ligand α- GalCer presented by CD1d α - GalCer Th1 cytokines APC NKT Perforin Granzyme B CD40/L FasL IL-12 M Taniguchi et at Ann Rev Immunol 21:483 (2003)
  • 26. Antigen Presenting Cells • Drive tumor Ag specific immune responses DC Mφ B cell Ag uptake Macropino- phagocytosis Ig receptor cytosis, mediated phagocytosis MHC High upon Inducible Constitutive, expression maturation (activation increases on dependent) activation Co-stimulator High upon Inducible Inducible delivery maturation
  • 27. Dendritic Cells (DCs) • Immature DCs in the periphery take up Ag (e.g., Langerhans’ cells in epidermis) • Activation associated maturation and migration to draining LN • Mature DCs present Ag to T cells – MHC class II +, B7+ • Most potent APC for naïve T cells
  • 28. DCs in Tumor Immunology High DC infiltration in clinically resected non-small cell lung cancer specimens correlated with better prognosis N Inoshima et at Clin Cancer Res 8:3480 (2002)
  • 29. DC Subsets • Myeloid DCs – Express CD11b – Derived from monocyte precursors – Activated by GM-CSF • Lymphoid DCs – Express CD8a – Derived from plasmacytoid precursors – Activated by IL-3 – Produce IL-12 and prime Th1 responses – Potential role in peripheral tolerance Note: maturation status or activation/suppression events may direct whether DC = activating or tolerising
  • 30. Lymphoid DCs in Tumor Immunology Lymphoid DCs transduce a tolerogenic signal – Spleen derived lymphoid DCs pulsed with Ag bearing irradiated cells were adoptively transferred into naïve mice – Recipient mice were then challenged with Ag – DCs that were unable to crossprime (β 2 M KO) were not tolerogenic TA Ferguson et at J Immunol 168:5589 (2002)
  • 31. DC subsets continued • DC1 (human) drive Th1 response – mature DC – CD8 α + B7.1+ • DC2 (human) drive Th2 response – Immature DC – CD8 α - B7.2+ • Plasmacytoid DCs (DC2?) – CD4+ IL-3R+ – Display markers/morphological features of plasma cells – Produce large amounts IFN- α / β upon exposure to viruses – Only DC subset shown to be directly activated by CpG DNA (via TLR-9)
  • 32. Immunity and Cancer http://press2.nci.nih.gov/sciencebehind/immune/immune31.htm